Future cancer vaccines may target antigens derived not from standard coding regions, but from the "dark genome." Dr. Radvanyi highlights that retro-transposable elements and endogenous retroviruses, activated in cancer, represent a vast, untapped source of tumor-specific antigens for novel immunotherapies.

Immuno-oncology is not a one-time fix because cancer cells are described as "smart" adversaries that quickly adapt and develop resistance. The future of treatment lies in staying a step ahead, constantly switching therapeutic mechanisms to outmaneuver the cancer's ability to learn.

An individual tumor can have hundreds of unique mutations, making it impossible to predict treatment response from a single genetic marker. This molecular chaos necessitates functional tests that measure a drug's actual effect on the patient's cells to determine the best therapy.

The same cancer-driving mutation behaves differently depending on the cell's internal "wiring." For example, a drug targeting a mutation works in melanoma but induces resistance in colorectal cancer due to a bypass pathway. This cellular context is why genetic data alone is insufficient.

Many blood cancers are better understood as "regulatory problems" driven by epigenetic failures—the systems controlling which genes are turned on or off. This shifts the therapeutic focus from targeting DNA mutations to developing drugs, like IDH inhibitors, that correct these underlying control mechanisms.

The next major advance in adjuvant kidney cancer will be a biomarker to select who needs treatment. The key is developing a Minimal Residual Disease (MRD) test based on the epigenome (e.g., chromatin modifications) rather than just ctDNA mutations. This is because the critical biological signals in RCC are found in epigenetic regulation, not just the genome.

By targeting MEK, which is downstream of RAS/RAF in the MAPK pathway, Immuneering's therapy can block a wider range of potential resistance mutations. This preempts the cancer's ability to adapt by mutating upstream proteins, a common failure point for drugs that target RAS directly.

Circulating tumor DNA (ctDNA) analysis allows for early detection of resistance mechanisms, such as secondary FGFR2 mutations, before tumors show growth on scans. This provides a potential window to adjust treatment strategies proactively, offering an advantage over traditional imaging-based monitoring.

Germ cell tumors are extremely sensitive to chemotherapy due to intrinsic biological factors, not the immune environment. Their DNA is relatively hypomethylated, leaving it more open to damage, and they have intact apoptosis mechanisms with low rates of P53 mutation. This explains why they respond so well to chemo but poorly to traditional checkpoint inhibitors.